IP Library › Granted Patent US 11,168,338
Granted Patent B2
US 11,168,338 · App. 16/535,199 · Granted Nov 9, 2021

RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci

Inventors: J. Keith Joung (Winchester, MA); Morgan Maeder (Brookline, MA)
Assignee: The General Hospital Corporation
C12N15/907C07K14/005C07K14/195C12N9/0071C12N9/1007C12N9/16C12N9/22C12N9/96C12N15/01C12N15/102C12N15/1031C12N15/11C12N15/63C12N15/85C12Y301/21004C07K2319/00C07K2319/01C07K2319/80C12N2310/20C12N2710/00033C12N2770/00033C12N2800/80C12Y114/11C12Y201/01C12Y301/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,168,338
App. No.
16/535,199
Granted
Nov 9, 2021
Kind
B2
Abstract

Methods and constructs for RNA-guided targeting of heterologous functional domains such as transcriptional activators to specific genomic loci.

Claims (12)

1. A fusion protein comprising catalytically inactive CRISPR associated 9 (dCas9) protein linked to a Heterochromatin Protein 1 (HP1).

2. The fusion protein of claim 1 , wherein the catalytically inactive Cas9 protein is from S. pyogenes.

3. The fusion protein of claim 2 , wherein the catalytically inactive Cas9 protein comprises mutations at D10, E762, H983, or D986; and at H840 or N863.

4. The fusion protein of claim 3 , wherein the mutations are:

(i) D10A or D10N, and

(ii) H840A, H840N, or H840Y.

5. The fusion protein of claim 1 , wherein the heterologous functional domain is linked to the N terminus or C terminus of the catalytically inactive Cas9 protein, with an optional intervening linker, wherein the linker does not interfere with activity of the fusion protein.

6. The fusion protein of claim 1 , further comprising one or both of a nuclear localization sequence and one or more epitope tags on the N-terminus, C-terminus, and/or in between the catalytically inactive CRISPR associated 9 (Cas9) protein and the heterologous functional domain, optionally with one or more intervening linkers.

7. The fusion protein of claim 6 , wherein the epitope tag is c-myc, 6His, or FLAG.

8. A nucleic acid encoding the fusion protein of claim 1 .

9. An expression vector comprising the nucleic acid of claim 8 .

10. A method of decreasing expression of a target gene in a cell, the method comprising expressing the fusion protein of claim 1 in the cell, and one or more guide RNAs directed to the target gene.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2019
From: JOUNG, J. KEITH; MAEDER, MORGAN
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 050906/0166 →
Continuity (6)
Continuation 14775869
Provisional Application 61799647 · Mar 15, 2013
Provisional Application 61838178 · Jun 21, 2013
Provisional Application 61838148 · Jun 21, 2013
Provisional Application 61921007 · Dec 26, 2013
Related Publication 20190376090A1 · Dec 12, 2019
Cited By (1)
US 12,215,343